MZ
Amphastar Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BAQSIMI® (Glucagon Nasal Powder) | Severe Hypoglycemia (Very Low Blood Sugar) | Approved/Commercial |
| Iron Sucrose Injection, USP | Iron Deficiency Anemia in Chronic Kidney Disease | Approved/Commercial |
| Teriparatide Injection | Osteoporosis | Approved/Commercial |
| Primatene® MIST (Epinephrine Inhalation Aerosol) | Mild, Intermittent Asthma | Approved/Commercial |
| Albuterol Sulfate Inhalation Aerosol | Bronchospasm (Asthma, COPD) | Approved/Commercial |
| Biosimilars Pipeline | Various (e.g., Diabetes, Oncology) | Pre-clinical to Phase 3 |
| Complex Injectable Generics Pipeline | Various | ANDA Filed / Development |
Leadership Team at Amphastar Pharmaceuticals
JY
Jack Y. Zhang
Co-Founder, President, and Chief Executive Officer
WJ
William J. Peters
Chief Financial Officer
MA
Michael A. Zasloff
Executive Vice President, General Counsel, and Secretary
RA
Richard A. Prins
Board Member
RB
Robert B. Chess
Board Member
GJ
Gary J. Matus
Board Member